NurExone Biologic (FRA:J90) Total Equity: €1.73 Mil (As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.32
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Total Equity?

NurExone Biologic FRA:J90 +0.63% 34 Total Equity is €1.73 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

NurExone Biologic's total equity for the quarter that ended in Mar. 2026 was €1.73 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NurExone Biologic Total Equity Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Total Equity Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
1.04 1.98 0.17 1.68 2.36

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 1.33 1.24 2.36 1.73
FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NurExone Biologic's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3.487-1.132
=2.36

NurExone Biologic's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2.722-0.99
=1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1.73 Mil mean?
NurExone Biologic (FRA:J90) has a Total Equity of €1.73 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for NurExone Biologic and its competitors.
Is NurExone Biologic's Total Equity too high?
NurExone Biologic's current Total Equity is €1.73 Mil. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Total Equity compare to VRTX and REGN?
NurExone Biologic's Total Equity of €1.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for NurExone Biologic and its competitors. NurExone Biologic's current Total Equity is €1.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Total Equity of €1.73 Mil. The current Total Equity is €1.73 Mil. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Total Equity is €1.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price